• Markets
  • icon
  • Companies
LDX · ASX

Lumos Diagnostics Holdings Ltd. (ASX:LDX)

AU$0.035

 -0.001 (-2.778%)
ASX:Live
27/05/2024 04:10:54 PM
HALO Ords GROWTH AUS Extreme Oversold All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

LDX Overview

LDX Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About LDX

Website

N/A

Telephone

Address

Description

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. It manages the provision of diagnostics goods and services. It operates through the United States and Australia geographical segments. The company was founded in 2015 and is headquartered in South Melbourne, Australia.

LDX Price Chart

Key Stats

Market Cap

AU$17.33M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.17

Trade Value (12mth)

AU$208,970.00

1 week

-18.6%

1 month

-36.36%

YTD

-53.33%

1 year

191.67%

All time high

1.3922899961471558

Key Fundamentals

EPS 3 yr Growth

-31.600%

EBITDA Margin

-61.70%

Operating Cashflow

-$14m

Free Cash Flow Return

-47.00%

ROIC

-43.70%

Interest Coverage

-2.70

Quick Ratio

0.60

Other Data

Shares on Issue (Fully Dilluted)

444m

HALO Sector

Next Company Report Date

20-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

LDX Announcements

Latest Announcements

Date Announcements

06 May 24

Lumos Achieves Key Phase 1 Milestone in Hologic Agreement

×

Lumos Achieves Key Phase 1 Milestone in Hologic Agreement

02 May 24

Lumos quarterly update video interview with CEO, Doug Ward

×

Lumos quarterly update video interview with CEO, Doug Ward

01 May 24

Notification regarding unquoted securities - LDX

×

Notification regarding unquoted securities - LDX

23 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

08 April 24

Lumos announces positive FebriDx paediatric study results

×

Lumos announces positive FebriDx paediatric study results

02 April 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

02 April 24

Application for quotation of securities - LDX

×

Application for quotation of securities - LDX

02 April 24

Change in substantial holding

×

Change in substantial holding

29 February 24

Change in substantial holding

×

Change in substantial holding

28 February 24

Appendix 4D and Half Year Report

×

Appendix 4D and Half Year Report

28 February 24

Half Year Results Investor Presentation

×

Half Year Results Investor Presentation

23 February 24

1H FY24 Results Investor Briefing Invitation

×

1H FY24 Results Investor Briefing Invitation

14 February 24

Change in substantial holding

×

Change in substantial holding

12 February 24

Lumos Appoints Henry Schein as US Distributor for FebriDx

×

Lumos Appoints Henry Schein as US Distributor for FebriDx

05 February 24

Lumos Investor Roadshow Presentation

×

Lumos Investor Roadshow Presentation

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 24

Investor Information Sessions

×

Investor Information Sessions

19 January 24

Notification regarding unquoted securities - LDX

×

Notification regarding unquoted securities - LDX

19 January 24

Proposed issue of securities - LDX

×

Proposed issue of securities - LDX

17 January 24

Change in substantial holding

×

Change in substantial holding

16 January 24

Additional Information Regarding Agreements with Hologic

×

Additional Information Regarding Agreements with Hologic

16 January 24

New Hologic Agreements Investor Briefing Presentation

×

New Hologic Agreements Investor Briefing Presentation

15 January 24

Investor Briefing on new Hologic Agreements

×

Investor Briefing on new Hologic Agreements

15 January 24

Notification of cessation of securities - LDX

×

Notification of cessation of securities - LDX

11 January 24

Lumos Signs Major Development and IP Agreements with Hologic

×

Lumos Signs Major Development and IP Agreements with Hologic

LDX Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.12 -0.41 -0.06 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.12 -0.41 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.9 -232.2 86.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.10 -0.10 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.14 -0.19 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -144.5 -3.2 72.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A -132.9 -561.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock N/A 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock N/A 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.48 0.12 0.05 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.27 0.04 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5,748.6 -86.1 -118.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 162 152 235 Lock Lock Lock
Basic m Lock Lock Lock Lock 162 152 235 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 25 16 16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 201.0 -36.6 -2.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 16 17 8 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 -12 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.7 -1,461.4 44.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock 3.4 -72.1 -41.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 97 172 141 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -14 -30 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.5 -108.9 67.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -56.2 -185.0 -61.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 4 5 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -34 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5.0 -127.6 54.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -58.4 -209.3 -96.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -20 -63 -13 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -20 -63 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.8 -212.9 78.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -79.7 -393.2 -85.2 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -15 -25 -14 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 11 6 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -11 -6 6 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 85 -15 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -22 -28 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -282.2 -26.1 48.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.9 -1.8 -0.9 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 60 12 5 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 131 54 38 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 10 9 12 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -49 -1 10 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 53 28 24 Lock Lock Lock
Equity $m Lock Lock Lock Lock 78 26 14 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 87 35 26 Lock Lock Lock
     Growth % Lock Lock Lock Lock 137.0 -59.8 -26.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -15.4 -117.4 -34.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -26.0 -242.4 -93.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -16.7 -53.8 -46.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -23.1 -103.1 -43.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -16.7 -40.6 -47.0 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -2.5 -35.3 -2.7 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.5 0.0 -1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -63.4 -4.4 71.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.8 1.0 0.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.6 0.9 0.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 78.7 59.4 50.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -33.7 -133.3 -116.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.5 3.8 6.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 4.1 5.6 8.4 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.8 18.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 24.0 13.2 10.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -79.7 -393.2 -85.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -15.4 -117.4 -34.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -15.4 -117.4 -34.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.7 2.1 2.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -26.0 -242.4 -93.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock N/A 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock N/A -242.4 -93.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 88.4 64.7 43.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 81.8 95.7 58.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 170.2 160.4 101.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 90.8 59.3 34.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 79.4 101.1 66.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

LDX Shortsell

Frequently Asked Questions

The current share price of Lumos Diagnostics Holdings Ltd. (LDX:ASX) is AU$0.035.
The 52-week high share price for Lumos Diagnostics Holdings Ltd. (LDX:ASX) is AU$0.17.
The 52-week low share price for Lumos Diagnostics Holdings Ltd. (LDX:ASX)? is AU$0.01.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) does not pay a dividend.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) does not pay a dividend.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) has a franking level of 0.0%.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) is classified in the Healthcare.
The current P/E ratio for Lumos Diagnostics Holdings Ltd. (LDX:ASX) is .